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Factors driving the increase in drug-resistant tubercu-
losis (TB) in the Eastern Cape Province, South Africa, are 
not understood. A convenience sample of 309 drug-sus-
ceptible and 342 multidrug-resistant (MDR) TB isolates, 
collected July 2008–July 2009, were characterized by 
spoligotyping, DNA fingerprinting, insertion site mapping, 
and targeted DNA sequencing. Analysis of molecular-
based data showed diverse genetic backgrounds among 
drug-sensitive and MDR TB sensu stricto isolates in con-
trast to restricted genetic backgrounds among pre–exten-
sively drug-resistant (pre-XDR) TB and XDR TB isolates. 
Second-line drug resistance was significantly associated 
with the atypical Beijing genotype. DNA fingerprinting and 
sequencing demonstrated that the pre-XDR and XDR 
atypical Beijing isolates evolved from a common progeni-
tor; 85% and 92%, respectively, were clustered, indicating 
transmission. Ninety-three percent of atypical XDR Beijing 
isolates had mutations that confer resistance to 10 anti-TB 
drugs, and some isolates also were resistant to para-ami-
nosalicylic acid. These findings suggest the emergence of 
totally drug-resistant TB.
The emergence of drug-resistant tuberculosis (TB) is of major concern to TB control in South Africa. 
A countrywide survey in 2002 revealed that 1.8% of all 
new TB patients and 6.7% of TB patients who had under-
gone previous treatment had multidrug-resistant (MDR) 
TB (resistant to at least isoniazid and rifampin) (1). This 
finding translates to an estimated annual case load of 
13,000 MDR TB cases, placing South Africa fourth among 
countries where MDR TB is highly prevalent (1). How-
ever, this number may be an underestimation; 2 recent 
studies (2,3) suggested that the proportion of MDR TB 
cases may be substantially higher than the World Health 
Organization (WHO) estimate (3). In addition, only 4,143 
of the 9,070 patients (46%) who received a diagnosis of 
MDR TB in 2009 received treatment, possibly because of 
resource constraints, creating a situation in which control 
was bound to fail (4). This conclusion is supported by the 
diagnosis of 594 extensively drug- resistant (XDR) TB 
cases (MDR plus additional resistance to a fluoroquino-
lone and any second-line injectable drug) in that year (4). 
The cure rate of patients with drug-resistant TB is <50% 
for those with MDR TB (5), whereas culture conversion 
was observed in only 19% of XDR TB case-patients dur-
ing the follow-up period, irrespective of HIV status (6).
Most cases of MDR TB and XDR TB in South Af-
rica have been detected in KwaZulu-Natal, Western Cape, 
and Eastern Cape Provinces (4). Statistics from the Eastern 
Cape showed the largest increase in the number of MDR 
TB cases, rising from 836 cases in 2006 to 1,858 cases in 
2009 (2.2 fold increase) (4). The reason for this dramatic 
increase in MDR TB cases remains to be determined.
Molecular epidemiologic data from the neighboring 
Western Cape Province have demonstrated that MDR TB is 
spread by primary transmission (7–9), which accounts for 
nearly 80% of reported MDR TB cases (2). To date, only 
1 molecular epidemiologic study has been reported for the 
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Eastern Cape (10), and it showed that 50% of rifampin-re-
sistant TB isolates (including MDR TB isolates) belonged 
to the Beijing genotype and that “atypical” Beijing strains 
were significantly overrepresented. These strains harbored 
rare mutations in the inhA gene promoter (G-17A) and 
rpoB gene (GAC→GTC nucleotide substitutions in codon 
516), which have previously been associated with a high 
fitness cost (11). The authors demonstrated that the spread 
of these strains was facilitated by HIV co-infection, thereby 
raising concern for the spread of drug-resistant strains in 
vulnerable populations (10).
A recent epidemiologic study conducted in the Eastern 
Cape estimated that 75.6% of XDR TB cases with complete 
data were a result of ongoing transmission (12). Treatment 
outcomes were dismal; 58% of case-patients died within 
1 year, and culture conversion was observed in only 8.4% 
of case-patients after 143 days of treatment (12), raising 
concern that these patients had an untreatable form of TB. 
This situation is similar to the Tugela Ferry outbreak in 
KwaZulu-Natal Province (13), which highlighted the need 
for improved basic control measures, including rapid diag-
nostics and infection control methods (14).
This study aimed to describe the Mycobacterium tu-
berculosis strain population structure among MDR TB and 
XDR TB case-patients in Eastern Cape Province, South Af-
rica, in order to determine whether the epidemic was driven 
by acquisition or transmission of resistance and to describe 
the extent of resistance within these strains. These findings 
will inform TB control efforts to better implement mea-
sures to curb emergence or the spread of drug-resistance.
Materials and Methods
Study Population
Sputum specimens were collected from persons at 
high-risk for suspected TB (previously treated case-pa-
tients and close contacts of known patients with drug- resis-
tant cases) in accordance with the National TB Control Pro-
gram. Specimens that were collected at healthcare facilities 
in the Eastern Cape Province were submitted to the Na-
tional Health Laboratory Service (NHLS) in Port Elizabeth 
for TB drug susceptibility testing (DST). From July 2008 
through July 2009, a convenience sample of sputum cul-
tures, shown to be either fully drug-susceptible or resistant 
to at least isoniazid and rifampin (MDR TB) by the NHLS, 
was submitted to Stellenbosch University in Cape Town 
for subsequent genotyping. Only limited demographic 
and clinical data were available for each patient: a unique 
identifier (assigned by the NHLS), the date sputum was 
obtained, the name of the clinic/hospital where the sample 
originated, and the routine DST pattern. The unique identi-
fier was used to identify the first available isolate from 309 
drug-susceptible and 342 MDR TB case-patients included 
in the study. This study was approved by the ethics com-
mittee of Stellenbosch University, Faculty of Health Sci-
ences (N09/11/296).
Drug Susceptibility Testing
Sputum samples were processed by the NHLS for rou-
tine TB diagnosis by smear microscopy and culture. Each 
sputum specimen was decontaminated by using the stan-
dard N-acetyl-L-cysteine-sodium hydroxide method and 
cultured in mycobacteria growth indicator tube (MGIT) 
960 medium until a positive growth index was observed. 
DST was done by the indirect proportion method with the 
BACTEC MGIT 960 system (BD Bioscience, Sparks, MD, 
USA), according to the manufacturer’s instructions. We 
initially tested resistance against isoniazid and rifampin, 
followed by testing for resistance against streptomycin and 
ethambutol if the isolate was resistant to either isoniazid 
or rifampin. Second-line DST was done in 7H10 medium 
containing 2 µg/mL of ofloxacin, 4 µg/mL of amikacin, or 
5 µg/mL of ethionamide. DST for para-aminosalicylic acid 
was done at Stellenbosch University in MGIT 960 medium 
containing 4.0 µg/mL, 8 µg/mL, and 16 µg/mL of para-
aminosalicylic acid (15).
Molecular-based Analysis
Crude DNA was prepared by boiling a 200-µL aliquot 
of a mycobacteria-positive MGIT culture, and this was 
used as a template for subsequent PCR analysis (16). Each 
isolate was spoligotyped by using the international stan-
dardized method (17) and grouped into genotypes accord-
ing to previously described spoligotype signatures (18). 
Beijing genotype strains were subclassified as either “typi-
cal” or “atypical,” according to the presence or absence of 
an IS6110 insertion in the noise transfer function (NTF) 
region (19,20). The atypical Beijing genotype strains were 
further classified by using the international standardized 
IS6110 DNA fingerprinting method (21). For atypical 
Beijing strains that were drug-sensitive according to DST, 
sensitivity to isoniazid and rifampin was confirmed by se-
quencing the katG and rpoB genes. In MDR atypical Bei-
jing strains, mutations conferring resistance to isoniazid, 
rifampin, ethambutol, pyrazinamide, ofloxacin, streptomy-
cin, amikacin, kanamycin, and capreomycin were identi-
fied by sequencing the inhA promoter and the katG, rpoB, 
embB, pncA, gyrA, and rrs genes, respectively (22,23). Iso-
lates were grouped as as follows: MDR TB sensu stricto 
(MDR TB ss, that is, MDR strains excluding identified pre-
XDR, MDR plus additional resistance to either a fluoro-
quinolone or any second-line injectable anti-TB drug) [24] 
and XDR strains); pre-XDR TB; or XDR TB, according to 
high confidence mutations. This method of grouping was 
selected because routine DST was not done for all of the 
anti-TB drugs on all of the isolates. Furthermore, a poor 
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correlation was observed between high-confidence muta-
tions and routine second-line DST. Isolates were consid-
ered to belong to the same cluster (implying ongoing trans-
mission) if identical mutations were observed in all of the 
genes sequenced.
Results
A convenience sample of 309 drug-sensitive and 342 
MDR TB isolates from patients from Eastern Cape Province 
was collected during the study period. These isolates were 
submitted to Stellenbosch University for molecular-based 
analysis. Analysis of the population structure of these iso-
lates by spoligotyping identified 52 and 29 different spoligo-
type patterns among drug-sensitive and MDR TB strains, re-
spectively. Among drug-sensitive and MDR isolates, 22/52 
and 14/29 spoligotype patterns were previously recorded in 
the fourth international spoligotyping (SpolDB4) database. 
These represented 275 (89.0%) of 309 drug-sensitive iso-
lates and 327 (95.6%) of 342 MDR isolates. Notably, 84% 
of MDR isolates constituted only 3 different spoligotypes 
(Table 1), namely, Beijing, LAM3, and LAM4. These find-
ings indicate transmission of these strains.
Table 1 shows the classification of spoligotypes, ac-
cording to the degree of drug resistance, in which drug 
resistance is expressed as the result of culture-based or 
molecular-based DST. In this study, we used molecular-
based DST to define the extent of drug-resistance in rou-
tinely diagnosed MDR TB isolates. Accordingly, 119 
(38.5%) of the drug-susceptible isolates and 236 (69.0%) 
of the MDR TB isolates were of the Beijing genotype. 
Subclassification of Beijing genotype strains showed 
that 11(9.2%) of 119 drug-sensitive and 217 (91.9%) of 
236 MDR strains belonged to the “atypical” subgroup of 
the Beijing genotype, as indicated by the absence of an 
IS6110 element in the NTF region.
Analysis of mutations conferring resistance to first- and 
second-line anti-TB drugs enabled grouping of the MDR 
isolates: 136 MDR ss, 98 pre-XDR, and 108 XDR. Using 
these groupings, we found that isolates with a higher degree 
of resistance were more likely to have an atypical Beijing 
genotype (drug sensitive: 11/309 [3.6%, 95% CI 1.8%–
6.3%], MDR ss: 29/136 [21.3%, 95% CI 14.8%–29.2%] vs. 
pre-XDR: 85/98 [86.7%, 95% CI 78.4%–92.7%] vs. XDR: 
103/108 [95.4%, 95% CI  89.5%–98.5%]).
We analyzed DNA sequencing data for the first avail-
able isolate from each patient infected with an MDR atypi-
cal Beijing strain (n = 217) and performed IS6110 finger-
printing for a subset of these isolates (n = 110) to establish 
whether the overabundance of the atypical Beijing genotype 
among patients with pre-XDR TB and XDR TB strains re-
flected ongoing transmission. IS6110 DNA fingerprinting 
showed that all of these patients were infected with closely 
related atypical Beijing strains with only minor differences 
in the banding patterns (online Technical Appendix, Figures 
1, 2, wwwnc.cdc.gov/EID/article/19/3/12-0246-Techapp1.
pdf), thereby suggesting clonal dissemination.
The online Technical Appendix Table shows that 216 
(99.5%) of 217 of the MDR atypical Beijing genotype 
strains harbored an identical katG (AGC315ACC) muta-
tion, whereas 209 (94.9%) of 217 had a distinctive rrs 
(A513C) gene mutation. This finding suggests that these 
mutations were acquired before dissemination. Subse-
quently, resistance to rifampin, ethambutol, pyrazinamide, 
amikacin, and ofloxacin was acquired in various combi-
nations. Of the 29 atypical Beijing MDR ss isolates, 22 
(75.9%) were grouped into 4 clusters according to mutations 
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Table 1. Spoligotype classification of drug-sensitive and MDR TB isolates, Eastern Cape Province, South Africa, 2008–2009* 
Spoligotype 
family† ST no. 
Culture-based DST, no. (%)  Molecular-based DST, no. (%) 
Sensitive MDRss Pre-XDR XDR   MDRss Pre-XDR XDR 
Atypical Beijing 1 11 (3.6) 41 (27.0) 98 (92.5) 78 (92.9)  29 (22.5) 85 (87.6) 103 (95.4) 
Typical Beijing  1 108 (35.0) 19 (12.5) 0 0  18 (14.0) 1 (1.0) 0 
 H 36; 47; 50; 62 7 (2.3) 2 (1.3) 1 (0.9) 0  2 (1.6) 1 (1.0) 0 
 LAM3 33; 130; 211 66 (21.4) 12 (7.9) 2 (1.9) 0  12 (9.3) 0 (0) 0 
 LAM4 60; 811 6 (1.9) 32 (21.1) 4 (3.8) 2 (1.9)  29 (22.5) 3 (3.1) 2 (1.9) 
 LAM (other) 4; 20; 42; 398 7 (2.3) 1 (0.7) 0 1 (1.2)  1 (0.8) 0 1 (0.9) 
 MANU2 1247 0 0 0 2 (2.4)  1 (0.8) 0 1 (0.9) 
 S 34; 71 8 (2.6) 8 (5.3) 0 1 (1.2)  8 (6.2) 0 1 (0.9) 
 T 44; 53; 73; 254; 926; 
1240 
51 (16.5) 18 (11.8) 0 0  13 (10.1) 5 (5.2) 0 
 U 443; 519; 790 1 (0.3) 2 (1.3) 0 0  2 (1.6) 0 0 
 X 18; 92; 119; 1751 6 (1.9) 3 (2.0) 0 0  3 (2.3) 0 0 
 CAS 21; 26; 1092 4 (1.3) 0 0 0  0 0 0 
 Orphan Not assigned 34 (11.0) 14 (9.2) 1 (0.9) 0  11 (8.5) 2 (2.1) 0 
Total  309 152 106 84  129 97 108 
 Total MDR    342    334‡  
*MDR TB, multidrug-resistant tuberculosis; ST, shared type (17); DST, drug susceptibility testing; MDRss, MDR sensu stricto; Pre-XDR, pre–extensively 
drug resistant; XDR, extensively drug resistant. 
†For Beijing isolates a distinction was made between typical and atypical based on the presence or absence of an IS6110 insertion in the noise transfer 
region (18,19). 
‡Molecular-based DST total differs from culture-based DST total, because some results were not available. 
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(mutation pattern [MP]) in the inhA promoter and the katG, 
rpoB, embB, pncA, rrs, and gyrA genes (cluster size ranged 
from 3 to 12 cases; online Technical Appendix Table: MP2, 
MP17, MP32, MP34), whereas 7 had unique MPs (online 
Technical Appendix Table 2: MP23, MP25, MP30, MP31, 
MP41, MP44, MP48). Similarly, the 85 atypical pre-XDR 
Beijing isolates showed 11 different MPs, of which 81 
(95.3%) were grouped into 7 clusters (cluster size ranged 
from 2 to 62 cases; online Technical Appendix Table: MP3, 
MP5, MP18, MP26, MP28, MP35, MP38). The genotype 
of the largest pre-XDR TB cluster was characterized by an 
inhA promoter mutation at position 17 and the katG AG-
C315ACC, rpoB GAC516GTC, embB ATG306ATA, rrs 
A513C, and rrs A1401G nucleotide substitutions as well as 
an insertion in the pncA gene at position 172G. This MP was 
characteristic of 81 (78.6%) of 103 of the atypical Beijing 
XDR TB isolates and, for ease of reference, will be called 
MP5 (online Technical Appendix Table). By contrast, 
only 3 of the 29 atypical Beijing MDR ss isolates showed 
the same mutation pattern for these genes, excluding the 
rrsA1401G mutation (MP2). Ten different atypical XDR 
Beijing MPs emerged from the MP5 progenitor by mutation 
in the gyrA gene. Of these, 6 MPs showed clustering (cluster 
size ranged from 2 to 46 cases, MP6–11), and 4 had unique 
mutations conferring ofloxacin resistance (MP12–16). Clus-
tering of both the pre-XDR and XDR genotypes suggests 
transmission after the acquisition of additional resistance. Of 
the remaining 22 atypical XDR Beijing isolates, 12 distinct 
resistance MPs were observed, of which 11 isolates were 
clustered (MP27) and 11 had unique genotypes (MP19–22, 
MP24, MP29, MP39–40, MP42–43, MP47).
Spatial analysis of the patients’ origins showed that 
pre-XDR and XDR isolates with an atypical Beijing geno-
type were found in 5 of 8 district municipalities (Figure; 
online Technical Appendix Table). The largest atypical 
pre-XDR Beijing genotype cluster (MP5) was identified 
in 4 adjacent district municipalities (online Technical Ap-
pendix Table), and the largest XDR TB cluster (MP6) 
was identified in 3 of these districts as well as in an ad-
ditional district, which suggests the past spread of these 
genotypes.
The presence of mutations in target genes known to 
confer resistance with high confidence indicated that 95.1% 
(98/103) of the atypical XDR Beijing isolates were resis-
tant to at least 10 anti-TB drugs: isoniazid, rifampin, eth-
ambutol, pyrazinamide, streptomycin, amikacin, kanamy-
cin, capreomycin, ethionamide, and ofloxacin. The extent 
of drug resistance in these isolates was underestimated by 
routine DST (Table 2). The correlation between molecular-
based drug-resistance and routine culture-based DST was 
99.6% for isoniazid, 100% for rifampin, 28% for etham-
butol, 92% for streptomycin, 93% for amikacin, 27% for 
capreomycin, 52% for ethionamide, and 86% for ofloxacin 
(Table 2). Routine DST for pyrazinamide, kanamycin, cy-
closerine, and para-aminosalicylic acid was not performed. 
DST for para-aminosalicylic acid was done at Stellenbosch 
University on 45 isolates; 9 showed resistance at a level of 
>4.0 µg/mL.
Discussion
Review of routine DST results highlights the severity 
of the drug-resistant TB epidemic in South Africa (4) and 
thereby emphasizes the urgent need for curbing the rising 
incidence of drug resistance in the country. This result can 
only be achieved by implementing appropriate intervention 
strategies based on knowledge of the mechanisms fueling 
this epidemic. Recently, molecular epidemiologic tech-
niques were used in combination with classical epidemio-
logic data to enhance understanding of the TB epidemic in 
different settings. Those studies have quantified the rela-
tive proportion of acquisition versus transmission and have 
described the population structure of M. tuberculosis over 
time (7,10,22,24,25). Using these approaches, we show 
that patients with MDR TB in the Eastern Cape could be di-
vided into 2 distinct groups: isolates from patients infected 
with MDR ss showed diverse genetic backgrounds, while 
isolates from patients infected with pre-XDR TB and XDR 
TB showed restricted genetic backgrounds.
The finding that the pre-XDR TB and XDR TB strains 
are genetically distinct when compared to the MDR ss 
strains is counterintuitive because we would expect all 
MDR TB strains to have had an equal chance of acquiring 
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Table 2. Correlation of culture-based and molecular-based drug-susceptibility testing among atypical Beijing isolates, South Africa, 
2008–2009* 
Drug/gene 
CB-DST R, MB-
DST R 
CB-DST S, MB-
DST S 
CB-DST R, MB-
DST S 
CB-DST S, MB-
DST R Total Correlation, % 
INH/katG 217 9 1 0 227 99.6 
RIF/rpoB 219 9 0 0 228 100 
STR/rrs500 191 6 2 16 215 91.6 
EMB/embB 56 5 2 152 215 28.4 
ETH/inhA promoter 76 25 5 86 192 52.6 
OFL/gyrA 78 93 0 29 200 85.5 
AMK/rrs1400 167 32 7 9 215 92.6 
CAP/rrs1400 21 38 1 155 215 27.4 
*CB-DST, culture-based drug susceptibility testing; R, resistant; MB-DST, molecular-based DST; S, sensitive; INH, isoniazid; RIF, rifampin; STR, 
streptomycin; EMB, ethambutol; ETH, ethionamide; OFL, ofloxacin; AMK, amikacin; CAP, capreomycin. 
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resistance to second-line anti-TB drugs. The absence of 
second-line resistance among a large number of different 
MDR TB genotypes suggests that under the current MDR 
TB treatment regimen, acquisition of additional resistance 
in MDR ss strains is reduced. Conversely, analysis of the 
DNA sequencing data showed a significant association be-
tween the atypical Beijing genotype and mutations con-
ferring second-line resistance. This demonstrates that this 
genotype has acquired resistance to the level of pre-XDR 
TB, which in turn has spread and thereafter has acquired 
additional resistance to the level of XDR TB, followed 
again by transmission. An alternative explanation would 
be that the atypical Beijing genotype acquires resistance 
by conferring mutations more readily than other geno-
types. However, the convergent evolution of 7 different 
mutations within a single genotype is highly unlikely.
Analysis of the locations of the pre-XDR TB case-pa-
tients infected with this clone shows that it had a wide geo-
graphic distribution, which suggests that this genotype has 
been in circulation for an extended period. This conclusion 
was further supported by the analysis of the evolutionary 
order in which resistance was acquired (online Technical 
Appendix Table), which showed that the ancestral clone 
first acquired resistance to isoniazid and streptomycin. This 
could be explained by the treatment regimen used in the 
early 1960s, which was based on the combination of isonia-
zid and streptomycin (26). A similar conclusion was drawn 
from whole genome sequence data which predicted that mu-
tations conferring resistance to isoniazid and streptomycin 
were deeply rooted in the atypical Beijing genotype (27).
Given the extent of resistance in pre-XDR TB strains 
and the extremely limited treatment options available, the 
emergence of ofloxacin resistance was inevitable. This idea 
was supported by our molecular-based analysis of the XDR 
TB isolates, which demonstrated that resistance to a fluo-
roquinolone had been acquired independently on several 
different occasions (several different gyrA mutations were 
observed), followed by amplification through transmission 
(clustering of XDR phenotypes was observed). However, 
the true extent of acquisition may be higher than predicted, 
given that the XDR TB isolates were cultured from samples 
from patients who resided in different district municipali-
ties, and contact was unlikely because of the long distances.
We suggest that the absence of routine second-line drug 
susceptibility testing and the treatment of MDR TB with 
an inadequate standardized regimen, according to the 2004 
guidelines (www.sahealthinfo.org/tb/mdrtbguidelines.pdf) 
(6 months’ intensive phase: kanamycin, ethionamide, pyra-
zinamide, ofloxacin, and cycloserine or ethambutol; 12–18 
months continuation phase: ethionamide, ofloxacin, and cy-
closerine or ethambutol) (28) may have led to the inappro-
priate treatment of undiagnosed pre-XDR TB cases. This 
regimen would have prolonged the period of infectiousness 
leading to transmission to close contacts and increased the 
risk of amplification of resistance (28,29). This problem has 
been recently addressed with the implementation of a re-
vised treatment regimen (28) as well as routine second-line 
DST, which is now done on all isolates shown to be re-
sistant to rifampin. However, these tests are culture-based, 
which exacerbates diagnostic delay and possible transmis-
sion. This situation can be partially resolved with the imple-
mentation of a genetic-based second-line drug susceptibil-
ity test (29). However, the extent of resistance associated 
with the atypical Beijing genotype makes treatment options 
extremely difficult as these isolates are resistant to all first-
line anti-TB drugs (isoniazid, rifampin, ethambutol, pyra-
zinamide and streptomycin) and many of the second-line 
drugs (amikacin, kanamycin, ofloxacin, ethionamide, cap-
reomycin). A limited number of isolates were also resistant 
to para-aminosalicylic acid. This suggests that the atypical 
Beijing genotype clone is evolving toward total drug resis-
tance (defined as in vitro resistance to all first-line drugs, as 
well as aminoglycosides, cyclic polypeptides, fluoroquino-
lones, thioamides, serine analogs, and salicylic acid deriva-
tives [30]) with acknowledgment of WHO’s concern over 
the definition (31). Our molecular-based results are in ac-
cordance with a recent study from the Eastern Cape, which 
documented extremely poor treatment outcomes for XDR 
TB case-patients (12). The authors found that these patients 
experienced a high death rate (58.4%) and low culture-con-
version rates (8.4%) over a follow-up period of 143 days. 
They concluded that only 1.7 drugs per patient could be 
regarded as “effective” on the basis of DST results, previ-
ous treatment records, or both. Given that this study was 
conducted concurrently with ours, it is highly likely that 
a large proportion of their patients were also infected with 
XDR TB strains with an atypical Beijing genotype. Thus, 
the poor treatment outcome may be related to the extent of 
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Figure. District municipalities in the Eastern Cape Province, 
South Africa. Map courtesy of F. W. van Zyl.
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drug-resistance; however, we cannot exclude the possibility 
that the atypical Beijing genotype contributes to illness and 
death. A further concern is the knowledge that this clone 
is now spreading to other provinces in South Africa, pos-
sibly due to migration. In Western Cape Province, an esti-
mated 55% of XDR TB case-patients harbor isolates with 
the atypical Beijing genotype (32).
We acknowledge that this study has several limita-
tions. First, clinical data were not available for this study, 
and thus it was not possible to establish the effects of drug 
resistance on treatment outcome. However, we do not be-
lieve that the strains reported by Kvasnovsky et al. (12) 
differ from those analyzed in this study because the stud-
ies were conducted concurrently. Second, our analysis of 
a convenience sample may have led to an overestimation 
of the proportion of pre-XDR TB and XDR TB cases 
in Eastern Cape Province. Third, our use of mutational 
data to categorize patient isolates as MDR ss, pre-XDR, 
and XDR is not the accepted standard. However, genetic 
DST has been endorsed by WHO for first-line anti-TB 
drugs, and mounting evidence indicates that high confi-
dence mutations accurately predict second-line drug re-
sistance (33).
The diagnostic dilemma facing TB control managers 
in Eastern Cape Province is how to rapidly identify case-
patients at risk of harboring the atypical Beijing genotype 
to prioritize DST, ensure patient isolation, and adminis-
ter appropriate treatment. Previous studies have shown a 
strong association between inhA promoter mutations and 
pre-XDR TB and XDR TB (34). Given that the Geno-
type MTBDRplus test (35) has been implemented as the 
diagnostic standard in most NHLS laboratories in South 
Africa, we propose that this test could be used as a rapid 
screening tool to identify patients harboring drug-resis-
tant atypical Beijing strains (34). To contain the spread 
of this virtually untreatable form of TB, control managers 
must make use of this information.
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